Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

Shares of Fulcrum Therapeutics (FULC) , a clinical-stage company, have plummeted 58% in the past month compared with the industry's 2.7% decline. FULC has also underperformed in the sector and the S&P 500 in the past month, as seen in the chart below. FULC Stock Underperforms the Industry, Sector & the S&P 500 Zacks Investment Research Image Source: The dip in the stock price was primarily observed after the company faced a major setback in September when it announced disappointing top-line data from a late ...